Deutsche Bank Ag\ Annexon, Inc. Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in Annexon, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 508,055 shares of ANNX stock, worth $2.61 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

508,055

Previous 495,690 2.49%

Holding current value

$2.61 Million

Previous $2.43 Million 23.85%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$4.49 - $7.2 $55,518 - $89,028	12,365 Added 2.49%	508,055 $3.01 Million
Q2 2024 Aug 14, 2024	BUY	$4.33 - $6.79 $1.47 Million - $2.31 Million	339,807 Added 217.99%	495,690 $2.43 Million
Q1 2024 May 15, 2024	SELL	$4.03 - $7.81 $4,509 - $8,739	-1,119 Reduced 0.71%	155,883 $1.12 Million
Q4 2023 Feb 14, 2024	BUY	$1.63 - $4.63 $255,913 - $726,919	157,002 New	157,002 $712,000
Q2 2022 Aug 11, 2022	SELL	$2.11 - $4.06 $35,709 - $68,711	-16,924 Reduced 11.77%	126,812 $478,000
Q1 2022 May 13, 2022	BUY	$2.73 - $11.94 $340,682 - $1.49 Million	124,792 Added 658.74%	143,736 $392,000
Q4 2021 Feb 11, 2022	BUY	$11.49 - $22.0 $11,570 - $22,154	1,007 Added 5.61%	18,944 $218,000
Q3 2021 Nov 04, 2021	SELL	$16.35 - $23.4 $9,384 - $13,431	-574 Reduced 3.1%	17,937 $334,000
Q2 2021 Aug 11, 2021	BUY	$17.81 - $27.48 $16,581 - $25,583	931 Added 5.3%	18,511 $417,000
Q1 2021 May 13, 2021	BUY	$22.0 - $35.01 $135,146 - $215,066	6,143 Added 53.71%	17,580 $489,000
Q4 2020 Feb 16, 2021	BUY	$20.81 - $30.55 $74,250 - $109,002	3,568 Added 45.34%	11,437 $286,000
Q3 2020 Nov 12, 2020	BUY	$17.5 - $30.23 $137,707 - $237,879	7,869 New	7,869 $237,000

Others Institutions Holding ANNX

# of Institutions

146

Shares Held

102M

Call Options Held

178K

Put Options Held

159K

View Full List

About Annexon, Inc.

Ticker ANNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,617,700
Market Cap $244M
Description
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...

More about ANNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account